HUE046924T2 - Módszerek és készítmények Barth szindróma megelõzésében vagy kezelésében történõ alkalmazásra - Google Patents

Módszerek és készítmények Barth szindróma megelõzésében vagy kezelésében történõ alkalmazásra

Info

Publication number
HUE046924T2
HUE046924T2 HUE14756991A HUE14756991A HUE046924T2 HU E046924 T2 HUE046924 T2 HU E046924T2 HU E14756991 A HUE14756991 A HU E14756991A HU E14756991 A HUE14756991 A HU E14756991A HU E046924 T2 HUE046924 T2 HU E046924T2
Authority
HU
Hungary
Prior art keywords
barth
syndrome
prevention
compositions
treatment
Prior art date
Application number
HUE14756991A
Other languages
English (en)
Hungarian (hu)
Inventor
D Travis Wilson
Mark Bamberger
Original Assignee
Stealth Biotherapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stealth Biotherapeutics Corp filed Critical Stealth Biotherapeutics Corp
Publication of HUE046924T2 publication Critical patent/HUE046924T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
HUE14756991A 2013-03-01 2014-02-28 Módszerek és készítmények Barth szindróma megelõzésében vagy kezelésében történõ alkalmazásra HUE046924T2 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361771642P 2013-03-01 2013-03-01
US201361771534P 2013-03-01 2013-03-01
US201361839753P 2013-06-26 2013-06-26

Publications (1)

Publication Number Publication Date
HUE046924T2 true HUE046924T2 (hu) 2020-03-30

Family

ID=51428869

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE14756991A HUE046924T2 (hu) 2013-03-01 2014-02-28 Módszerek és készítmények Barth szindróma megelõzésében vagy kezelésében történõ alkalmazásra

Country Status (9)

Country Link
US (5) US9687519B2 (enExample)
EP (2) EP2961420B1 (enExample)
JP (4) JP6518197B2 (enExample)
CN (3) CN115990242A (enExample)
CA (1) CA2916880C (enExample)
DK (1) DK2961420T3 (enExample)
ES (1) ES2750258T3 (enExample)
HU (1) HUE046924T2 (enExample)
WO (1) WO2014134554A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015507611A (ja) * 2011-12-09 2015-03-12 ステルス ペプチドズ インターナショナル インコーポレイテッド 芳香族カチオン性ペプチドおよびその使用
CA2916884C (en) 2013-03-01 2021-02-09 Stealth Biotherapeutics Corp Methods for the treatment of mitochondrial disease
US9687519B2 (en) 2013-03-01 2017-06-27 Stealth Biotherapeutics Corp Methods and compositions for the prevention or treatment of barth syndrome
CA2916977A1 (en) 2013-06-26 2014-12-31 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions
US9550981B2 (en) 2014-01-22 2017-01-24 University Of Washington Modified tafazzin proteins and methods of making and using the same
EP3230308B1 (en) 2014-12-12 2019-05-01 University of Washington Methods for treating and preventing cardiomyopathy
WO2018104172A1 (en) 2016-12-06 2018-06-14 Centre National De La Recherche Scientifique (Cnrs) Compounds for treating barth syndrome
IL269626B1 (en) 2017-04-05 2025-10-01 Stealth Biotherapeutics Corp Crystalline salt forms of boc–d–arg–dmt–lys–(boc)–phe–nh2
US10676506B2 (en) 2018-01-26 2020-06-09 Stealth Biotherapeutics Corp. Crystalline bis- and tris-hydrochloride salt of elamipretide
CN113383005A (zh) * 2018-12-18 2021-09-10 隐形生物治疗公司 靶向线粒体疾病的类似物

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
WO2003062784A2 (en) 2001-08-06 2003-07-31 Vanderbilt University Apparatus and methods for monitoring the status of a metabolically active cell
BRPI0105509B8 (pt) 2001-11-05 2021-05-25 Univ Minas Gerais formulações do peptídeo angiotensina-(1-7) usando as ciclodextrinas, lipossomas e o polímero plga
HUE027110T2 (en) 2003-02-04 2016-08-29 Cornell Res Foundation Inc Use of an aromatic cationic peptide
SI1599216T1 (sl) 2003-02-04 2014-02-28 Cornell Research Foundation, Inc. Postopek za preprečevanje mitohondrijskega permeabilnostnega prehoda
EP1597276A4 (en) * 2003-02-10 2006-11-29 Autogen Res Pty Ltd Therapeutic molecules
US20070026090A1 (en) 2003-09-05 2007-02-01 Oren Tirosh Treatment and prevention of inflammatory disease and mitochondrial dysfunction with high dose selenium
CA2554166C (en) 2004-01-23 2014-07-29 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
US8500720B2 (en) 2005-05-09 2013-08-06 Medtronic, Inc Method and apparatus for treatment of cardiac disorders
US20070265216A1 (en) * 2005-10-05 2007-11-15 Gross Richard W Enhanced medical treatment in diabetic cardiomyopathy
EP2012800A2 (en) * 2006-04-18 2009-01-14 Cortendo Invest, AB Methods and compositions for treating barth syndrome, cardiomyopathy, mitochondrial diseases and other conditions
WO2008137035A1 (en) 2007-05-02 2008-11-13 The Mclean Hospital Corporation Methods and compositions for mitochondrial replacement therapy
US20080318909A1 (en) 2007-06-14 2008-12-25 Sparagna Genevieve C Use Of Linoleic Compounds Against Heart Failure
US20090143279A1 (en) 2007-06-15 2009-06-04 Vamsi Krishna Mootha Methods and compositions for treating metabolic disorders
CN104056248A (zh) * 2008-02-26 2014-09-24 康奈尔大学 用于防止和治疗急性肾损伤的方法
US20110197294A1 (en) 2008-06-04 2011-08-11 Gottlieb Roberta A Compositions and methods for restoring mitochondrial electron transfer function
CN102171243A (zh) 2008-08-07 2011-08-31 益普生制药股份有限公司 N-端修饰的葡萄糖依赖性促胰岛素多肽(gip)类似物
EP3906933A1 (en) 2009-03-20 2021-11-10 The General Hospital Corporation d/b/a Massachusetts General Hospital D-arg-2'6'-dimethyltyrosine-lys-phe-nh2 for use in the prevention of secondary complications of burn injuries
US20120122957A1 (en) 2009-04-17 2012-05-17 The Salk Institute For Biological Studies Regulation of aging by modulation of mitochondrial function
WO2010132347A2 (en) 2009-05-11 2010-11-18 University Of Maryland, Baltimore Docosahexaenoic acid for the treatment of heart failure
JP5909182B2 (ja) 2009-08-12 2016-04-26 コーネル ユニヴァーシティー 代謝性症候群を予防し又は治療するための方法
US8470784B2 (en) * 2009-08-24 2013-06-25 Stealth Peptides International, Inc. Methods and compositions for preventing or treating ophthalmic conditions
JP2013506696A (ja) 2009-10-05 2013-02-28 コーネル ユニヴァーシティー 心不全の予防又は処置の方法
US8719939B2 (en) 2009-12-31 2014-05-06 Mcafee, Inc. Malware detection via reputation system
AU2010339410A1 (en) * 2009-12-31 2012-07-19 Stealth Peptides International, Inc. Methods for the prevention or treatment of vessel occlusion injury
US20110172312A1 (en) 2009-12-31 2011-07-14 Miller Guy M Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones
JP4643749B1 (ja) 2010-02-03 2011-03-02 昭和電工株式会社 表面被覆サーメット部材の耐酸化膜形成用の処理液
EP3511012A1 (en) 2010-02-26 2019-07-17 Cornell University Cornell Center For Technology, Enterprise & Commercialization ("CCTEC") Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy
EP3560508A1 (en) 2010-03-15 2019-10-30 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides
EP3290433A1 (en) * 2010-05-03 2018-03-07 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
US20130288985A1 (en) 2010-07-15 2013-10-31 The Schepens Eye Research Institute Inc. Compositions and methods of treatment of corneal endothelium disorders
EA201300215A1 (ru) 2010-08-06 2013-07-30 Эдисон Фармасьютикалз, Инк. Лечение митохондриальных болезней нафтохинонами
WO2012019032A1 (en) 2010-08-06 2012-02-09 Ampere Life Sciences, Inc. Treatment of mitochondrial diseases with vitamin k
US9241933B2 (en) 2011-03-01 2016-01-26 Pharnext Compositions for treating amyotrophic lateral sclerosis
EP3108975A1 (en) 2011-03-24 2016-12-28 Cornell University Aromatic-cationic peptides and uses of same
CN107496899A (zh) 2011-09-29 2017-12-22 梅约医学教育与研究基金会 芳族阳离子肽和使用它们的方法
CN106039282A (zh) 2011-10-17 2016-10-26 康奈尔大学 芳香族阳离子肽及其用途
CN106822868A (zh) * 2011-10-21 2017-06-13 斯特姆詹尼克斯公司 用于胞内传递生物活性分子的官能化纳米粒子
CA2865317A1 (en) 2012-02-22 2013-08-29 Stealth Peptides International, Inc. Methods and compositions for preventing or treating ophthalmic conditions
WO2013126775A1 (en) * 2012-02-23 2013-08-29 Cornell University Aromatic-cationic peptides and uses of same
AU2013329312A1 (en) 2012-10-09 2015-05-28 Massachusetts Institute Of Technology Treatment of age-related and mitochondrial diseases by inhibition of HIF-1 alpha function
BR112015009072A2 (pt) 2012-10-22 2017-07-04 Henry Ford Health Systems métodos para redução dos riscos associados à insuficiência cardíaca e fatores associados à mesma
US9687519B2 (en) * 2013-03-01 2017-06-27 Stealth Biotherapeutics Corp Methods and compositions for the prevention or treatment of barth syndrome
CA2916884C (en) 2013-03-01 2021-02-09 Stealth Biotherapeutics Corp Methods for the treatment of mitochondrial disease
CA2916977A1 (en) * 2013-06-26 2014-12-31 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions

Also Published As

Publication number Publication date
WO2014134554A1 (en) 2014-09-04
CN115990242A (zh) 2023-04-21
US20200345803A1 (en) 2020-11-05
JP2021098704A (ja) 2021-07-01
US20210401923A1 (en) 2021-12-30
US11083771B2 (en) 2021-08-10
JP2016511259A (ja) 2016-04-14
US20180147251A1 (en) 2018-05-31
US11771734B2 (en) 2023-10-03
EP2961420B1 (en) 2019-09-11
US20160228487A1 (en) 2016-08-11
JP6918046B2 (ja) 2021-08-11
EP3626252A1 (en) 2020-03-25
JP7381652B2 (ja) 2023-11-15
CN105407906A (zh) 2016-03-16
CA2916880A1 (en) 2014-09-04
CN115990241A (zh) 2023-04-21
DK2961420T3 (da) 2019-10-07
US12268724B2 (en) 2025-04-08
ES2750258T3 (es) 2020-03-25
JP2019147815A (ja) 2019-09-05
JP7072692B2 (ja) 2022-05-20
US9687519B2 (en) 2017-06-27
US20240156892A1 (en) 2024-05-16
EP2961420A1 (en) 2016-01-06
EP2961420A4 (en) 2016-08-17
JP6518197B2 (ja) 2019-05-22
JP2022116008A (ja) 2022-08-09
US11083772B2 (en) 2021-08-10
CA2916880C (en) 2021-02-09

Similar Documents

Publication Publication Date Title
IL283086A (en) Use of cannabidiol in the treatment of tuberous sclerosis complex
IL279752A (en) Polycyclic compounds and use thereof in the treatment of immune disorders
LTC3057969I2 (lt) Kompozicijos, naudojamos gydyti sutrikimams, susijusiems su kit
GB2548873B (en) Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
HUE046924T2 (hu) Módszerek és készítmények Barth szindróma megelõzésében vagy kezelésében történõ alkalmazásra
HUE053946T2 (hu) 4'-Fluor-nukleozidok, 4'-fluor-nukleotidok és analógjaik HCV kezelésére
HUE039997T2 (hu) Szulfamoilpirrolamid származékok és alkalmazásuk hepatitisz B kezelésére szolgáló gyógyszerekként
HUE040446T2 (hu) Szulfamoiltiofenamid-származékok és gyógyszerként történõ alkalmazásuk hepatitis B kezelésére
ZA201507155B (en) Substituted oxopyridine derivatives and use thereof in the treatment of cardiovascular disorders
IL240213A0 (en) Sulfamoyl-arylamides and their use as drugs for the treatment of jaundice b
HUE066811T2 (hu) Izoxazolin kompozíciók és azok felhasználása parazitafertõzések megelõzésében és kezelésében állatokban
HUE037347T2 (hu) Policiklusos karmaboilpiridon vegyületek és alkalmazásuk HIV fertõzések kezelésére
HUE037343T2 (hu) Policiklusos karmaboilpiridon vegyületek és alkalmazásuk HIV fertõzések kezelésére
HUE036224T2 (hu) C1-gátló készítmények örökletes angioödéma megelõzésében és kezelésében történõ alkalmazásra
SG10202101918RA (en) Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction
DK2945642T3 (da) Faktor 1 protein til anvendelse i behandling eller forebyggelse af sygdomme
SMT202500469T1 (it) Combinazione farmaceutica comprendente ponesimod e suo utilizzo nel trattamento della sclerosi multipla
LT2956471T (lt) Il-1beta inhibitoriaus kompozicija ir jos naudojimas
HUE051020T2 (hu) A ceramid szintjei a fertõzések kezelésében és megelõzésében
HUE057216T2 (hu) Genotípus-rétegzés cukorbetegség kezelésében és megelõzésében
PL3373922T3 (pl) Kompozycje i sposoby do stosowania do leczenia homocystynurii
MX2016003293A (es) Metodos y composiciones para el tratamiento de una infeccion por clamidia y enfermedades y trastornos relacionados.
IL243192B (en) Therapeutic agents for use in the prophylaxis and/or treatment of hyperkinetic movement disorders
EP3065548A4 (en) Fibrosis inhibiting compounds and methods of use thereof in the prevention or treatment of fibrosing diseases
PL2862576T3 (pl) Drobnoustroje i zawierające je kompozycje do stosowania do leczenia lub profilaktyki zapalenia sutka